Background and objective: Adverse drug reactions (ADRs) are the main safety concerns of
clinically used medications. Accumulating evidence has shown that ADRs can affect men …

The clinical guidelines that underpin the use of drugs for mental disorders are informed by
evidence from randomised controlled trials (RCTs). RCTs are performed to obtain marketing …

Current guidelines for patients with schizophrenia spectrum disease do not take sex
differences into account, which may result in inappropriate sex-specific treatment. In the …

Olanzapine is a commonly used drug in the treatment of schizophrenia, but its clinical
application has been restricted by metabolic-related side effects. In order to mitigate the …

Background Antipsychotic treatment may improve clinical insight. However, previous studies
have reported inconclusive findings on whether antipsychotics improve insight over and …

Background It remains a challenge to predict the long-term response to antipsychotics in
patients with schizophrenia who do not respond at an early stage. This study aimed to …

The majority of schizophrenia-affected individuals display deficiencies in multiple cognitive
domains such as attention, working memory, long-term memory, and learning, deficiencies …

Schizophrenia (SCZ) is associated with abnormal serum lipid profiles, but their relationship
is poorly understood. Mesencephalic astrocyte-derived neurotrophic factor (MANF) is an …

Depression occurs frequently in all phases of schizophrenia spectrum disorders. Altered
activity in the immune system is seen in both depression and schizophrenia. We aimed to …

The limited oral bioavailability remains an essential challenge of poorly water-soluble
amisupride (AMS). Herein, we designed a solid nanodispersion system of AMS (AMS-SN) …